Ligustrazine Alleviates Nitroglycerin-Induced Migraine by Regulating Mitochondrial Energy Metabolism Through the Concurrent Regulation of CypD, ANT, and PAR2.

Ligustrazine (Lig) is a compound that may help reduce migraine symptoms. Researchers studied its effects on migraines caused by nitroglycerin (NTG) in rats. They also tested it on nerve cells called PC12. The study focused on how Lig affects mitochondrial energy metabolism. Mitochondria are the cell's powerhouses and play a key role in energy production. The researchers looked at several factors, including oxidative stress and cell viability. They measured various parameters, such as reactive oxygen species and ATP levels. The study found that Lig improved migraine-like behaviors and overall mitochondrial function. It also regulated specific proteins involved in energy metabolism. This suggests that Lig could be a potential treatment for migraines by targeting these biological pathways. Further research is needed to confirm these findings and understand the mechanisms involved in detail. Clinical relevance: This research indicates that ligustrazine could potentially offer a new treatment option for migraine sufferers.